Showing results (251-260 of 686) with videos related to
Sort By:
Pageof 69
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 1, 2008
A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitisJonathan T Hlivko, Mitchell L Shiffman, R Todd Stravitz, et al.Journal of Clinical Medicine|October 14, 2023
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician PerspectiveWayne Eskridge, Donna R Cryer, Jörn M Schattenberg, et al.Scientific Reports|August 3, 2023
The crosstalking immune cells network creates a collective function beyond the function of each cellular constituent during the progression of hepatocellular carcinomaNicholas Koelsch, Faridoddin Mirshahi, Hussein F Aqbi, et al.Hepatology (Baltimore, Md.)|September 29, 2006
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current managementStephen H Caldwell, Maureane Hoffman, Ton Lisman, et al.The American Journal of Gastroenterology|September 23, 2003
Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndromeArun J Sanyal, Melissa J Contos, Richard K Sterling, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 24, 2025
Anti-Tumour Immunity Relies on Targeting Tissue Homeostasis Through Monocyte-Driven Responses Rather Than Direct Tumour CytotoxicityNicholas Koelsch, Faridoddin Mirshahi, Hussein F Aqbi, et al.Biorxiv : the Preprint Server for Biology|June 21, 2024
Anti-tumor immunity relies on targeting tissue homeostasis through monocyte-driven responses rather than direct tumor cytotoxicityNicholas Koelsch, Faridoddin Mirshahi, Hussein F Aqbi, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With FibrosisSudha S Shankar, Samuel J Daniels, Darren Robertson, et al.Hepatology (Baltimore, Md.)|June 15, 2007
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alphaMitchell L Shiffman, Jennifer Salvatore, Sarah Hubbard, et al.Hepatology Communications|May 24, 2021
coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis TreatmentElizabeth Clearfield, Veronica Miller, Joseph Nadglowski, et al.Pageof 69